A magic pill? A qualitative analysis of patients’ views on the role of antidepressant therapy in inflammatory bowel disease (IBD)

BMC Gastroenterology

Jane M Andrews³  Benjamin J Stewart²  Andrea L Gordon¹  Antonina A Mikocka-Walus² 

[1] School of Nursing and Midwifery, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia;School of Psychology, University of Adelaide, Adelaide, Australia;School of Medicine, University of Adelaide, Adelaide, SA, Australia

关键词: Patients’ views;    Mental health;    Inflammatory bowel disease;    Disease activity;    Antidepressants;   

Others  :  1121912
DOI  :  10.1186/1471-230X-12-93

 received in 2011-10-13, accepted in 2012-07-20,  发布年份 2012

【 摘 要 】

Background

Studies with healthy volunteers have demonstrated that antidepressants can improve immunoregulatory activity and thus they may have a potential to positively impact the disease course in inflammatory bowel disease (IBD), a chronic and incurable condition. However, patients’ views on the role of antidepressants in the management of their IBD are unknown. Thus, this study aimed to explore patients’ experiences and opinions regarding the effect of antidepressants on IBD course before possibly undertaking future treatment trials with antidepressants.

Methods

Semi-structured in-depth interviews with open-ended questions were conducted with a randomly selected sample of IBD patients recruited at the Australian public hospital IBD clinic and currently receiving antidepressants. A qualitative content analysis was undertaken to summarise patients’ responses. A Visual Analogue Scale was used to provide a quantitative assessment of patients’ experiences with antidepressants.

Results

Overall, 15 IBD sufferers currently on antidepressants (nine females, six males) were interviewed. All 15 reported a positive response to antidepressants reporting they improved their quality of life, with minimal side-effects. Five patients (33.3%) felt the antidepressant had specifically improved their IBD course. Three patients noted how they believed the reduction in feelings of stress mediated the positive influence of the antidepressant on IBD course. Ten patients (66.7%) felt the antidepressants had not specifically influenced their IBD. Nine patients (60.0%) had a generally positive attitude towards antidepressants, four patients (26.7%) were ambivalent, and two patients (13.3%) held a negative view towards antidepressants. Twelve patients (80.0%) stated that they would be willing to participate in clinical trials.

Conclusions

Antidepressants seem to be well tolerated by IBD patients. One third of patients reported an observable improvement of their IBD under the influence of this treatment. The positive attitude towards antidepressants in these participants may make the conduct of clinical trials to further assess for any specific role on IBD course feasible. However, due to a small sample size, a qualitative nature of this study and in light of the results of studies on other populations indicating reluctance to taking antidepressants at least in some patients, these results should be interpreted with caution until confirmed in quantitative studies.

【 授权许可】

   
2012 Mikocka-Walus et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G: Impact of Depressive Mood on Relapse in Patients With Inflammatory Bowel Disease: A Prospective 18-Month Follow-Up Study. Psychosom Med 2004, 66(1):79-84.
• [2]Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M: A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010, 105(9):1994-2002.
• [3]Addolorato G, Capristo E, Stefanini GF, Gasbarrini G: Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scan J Gastroenterol 1997, 32(10):1013-1021.
• [4]Timmer A, Preiss JC, Motschall E, Rucker G, Jantschek G, Moser G: Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011, 16(2):CD006913.
• [5]Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, Marmurowska-Michalowska H, Kandefer-Szerszen M: In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol J Pharmacol 2003, 55(3):353-362.
• [6]Mikocka-Walus A, Clarke D, Gibson P: Can antidepressants influence the course of inflammatory bowel disease (IBD)? A current state of research. European Gastroeneterology and Hepatology Review 2009, 5(1):48-53.
• [7]Mikocka-Walus A, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ: Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemol Ment Health 2006, 2:24. BioMed Central Full Text
• [8]Mikocka-Walus A, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ: "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol 2007, 7:38. BioMed Central Full Text
• [9]Mikocka-Walus A, Gordon A, Stewart B, Andrews JM: The role of antidepressants in the management of inflammatory bowel disease (IBD): A short report on a clinical case-note audit. Journal of Psychosomatic Research 2011, 72(2):165-167.
• [10]Goodhand JR, Greig FIS, Koodun Y, McDermott A, Wahed M, Langmead L, Rampton DS: Do Antidepressants Influence Disease Course in IBD? A Retrospective Case-Matched Observational Study. Inflammatory Bowel Diseases 2011. in press
• [11]Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM: Functional Gastrointestinal Disorders in Inflammatory Bowel Disease: Impact on Quality of Life and Psychological Status. J Gastroenterol Hepatol 2011, 26(5):916-923.
• [12]Mikocka-Walus A, Turnbull DA, Andrews JM, Moulding NT, Holtmann GJ: The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28(4):475-483.
• [13]Rang HP, Dale MM, Ritter JM: Rang & Dale's Pharmacology. 6 edn edition. Churchil Livingstone, London; 2007.
• [14]Creswell JW: Research design: Qualitative, quantitative, and mixed methods approaches. Sage, Thousand Oaks; 2003.
• [15]Grover M, Drossman DA: Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008, 8(6):715-723.
• [16]Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009, 58(3):367-378.
• [17]Spiller RC: Overlap between irritable bowel syndrome and inflammatory bowel disease. Dig Dis 2009, 27(Suppl 1):48-54.
• [18]Mearin F, Perello A, Balboa A: Irritable bowel syndrome and inflammatory bowel disease: Is there a connection? Gastroenterol Hepatol 2009, 32(5):364-372.
• [19]Bercik P, Verdu EF, Collins SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005, 34(2):6-7.
• [20]Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K: Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 1995, 762:474-476.
• [21]Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M: Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001, 21(2):199-206.
• [22]Ghia JE, Blennerhassett P, Collins SM: Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J Clin Invest 2008, 118(6):2209-2218.
• [23]Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM: Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009, 136(7):2280-2288. e2281-2284
• [24]Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, Lohr KN: Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. Drug Saf 2008, 31(10):851-865.
• [25]Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA: Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010, 24(1):35-53.
• [26]Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study http://www.nimh.nih.gov/trials/practical/stard/index.shtml webcite
• [27]Haddad PM: Do antidepressants cause dependence? Epidemiol Psichiatr Soc 2005, 14(2):58-62.
• [28]Shelton RC: The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006, 67(Suppl 4):3-7.
• [29]Glenmullen J: Coming Off Antidepressants. Robinson Publishing, London; 2006.
• [30]Bell RA, Franks P, Duberstein PR, Epstein RM, Feldman MD, Fernandez-Y-Garcia E, Kravitz RL: Suffering in silence: reasons for not disclosing depression in primary care. Annals of family medicine 2011, 9(5):439-446.
• [31]Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J: Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Medical care 2005, 43(12):1203-1207.
• [32]Russell J, Kazantzis N: Medication beliefs and adherence to antidepressants in primary care. N Z Med J 2008, 121(1286):14-20.